ClinicalTrials.gg
SuspendedNCT03097107Updated Feb 8, 2023

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

A Phase 2 interventional study of Saroglitazar Magnesium 1 mg and Saroglitazar Magnesium 2 mg in Dyslipidemias, sponsored by Zydus Therapeutics Inc.. Suspended at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Why this study was suspended
Management decision to suspend the study due to recruitment issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.

Planned enrollment
144th of 316
124 · median 105
Started
2017
with 11 others
Phase 2
66 of 349
2 open now
Registered
235th of 349
by date

Among the 349 studies in Dyslipidemias with a site in United States, this one is the 144th largest by planned enrollment of the 316 interventional ones that give a count, is one of 12 that started in 2017, is one of 66 in phase 2, and was the 235th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Dyslipidemias with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2, and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.

Read the detailed description

SARO.15.001.04 is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel arm, 12-week study designed to evaluate the safety and efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in patients with fasting triglyceride ≥500 mg/dL and ≤1500 mg/dL.

A total 124 subjects will be enrolled in a ratio of 1:1:1:1 to receive either Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, or placebo.

03

Conditions studied

  • Dyslipidemias

Keywords

  • hypertriglyceridemia
  • dyslipidemia
  • saroglitazar magnesium
  • lipid disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults subjects (≥18 year) of either gender.
  2. Average fasting TG-C ≥500 mg/dL and ≤1500 mg/dL (from Visits 2 and 2.1).
  3. Able and willing to give written and comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. History of pancreatitis within 6 months of the initial screening visit (Visit 1); patients that have an episode of pancreatitis after Visit 1 but before randomization will not be randomized.
  2. Patients with any history of pancreatitis may not be on GLP-1 agonists, DPP-4 inhibitors or pramlintide, with their last dose no sooner than 3 months prior to Visit 1; use of these agents by this population is prohibited throughout the duration of the trial and follow-up period. [Patients without a history of pancreatitis on these agents must be on a stable dose as of 3 months prior to Visit 1.]
  3. History of >5% weight gain or weight loss or participation in weight gain/loss program in past 3 months and not in the maintenance phase as of Visit 1.
  4. Diabetic (as per ADA guideline) patients with >9.5 %.
  5. Patients on prandial/rapid acting insulin, thiazolidinediones (TZDs) or glitazars in the 3 months prior to Visit 1.
  6. Patients on unstable doses of basal insulin (i.e., glargine, detemir, NPH) with unstable defined as a greater than 20% fluctuation in daily dose within the past 3 months.
  7. Patients on anti-obesity medications within 6 months of Visit 1 (orlistat, lorcaserin, phentermine, naltrexone/bupropion etc.).
  8. Patients on drugs that may promote weight loss (i.e., anti-epileptic agents such as topiramate, zonisamide and the anti-depressant bupropion) may not be taken, unless the dose is stable for 3 months and the indication for use is not weight loss.
  9. Patients on prohibited nutraceutical supplements contained in Annexure 1 that are unwilling to wash-out starting at Visit 1 (and abstain from use throughout the duration of the study, including follow-up).
  10. Patients with unexplained hematuria prior to or first noted during Visit 1.
  11. Patients with anemia who are undergoing repletion of deficiencies (iron, folate, B12) not in the maintenance phase as of Visit 1.
  12. Patients on concomitant lipid-lowering medications and not willing to participate in Lead-in/Run-in Phase (Please refer Lead-in/Run-in Phase).
  13. Patients having heart failure of class (III-IV), unstable angina, acute myocardial infarction, stroke, , any coronary revascularisation procedure and hospitalization for acute coronary syndrome and discharge within 6 months prior to screening.
  14. Patients with Left Ventricular dysfunction ( (LVEF) \<40%, as measured through ECHO).
  15. Uncontrolled hypertension (SBP >160 and/or DBP>100).
  16. An uncontrolled thyroid disorder

    • Uncontrolled hyperthyroidism is defined as any history of hyperthyroidism that has either not been treated with either radioactive iodine (RAI) and/or surgery -or- that has been treated with RAI and/or surgery, but has required ongoing continuous or intermittent use of thyroid hormone synthesis inhibitors (i.e., methimazole or proplythiouracil) within 6 months of Visit 1.
    • Uncontrolled hypothyroidism is defined as initiation of thyroid hormone replacement therapy or dose adjustment of replacement therapy within 3 months of Visit 1.
  17. History of GI malabsorption or history of gastric bypass, banding, or diversional bariatric surgery.
  18. History of active liver disease or gall stones or hepatic dysfunction demonstrated by and ALT ≥2 times of upper normal limit (UNL) or ≥1.5 times UNL at Visit 1.
  19. History of myopathies or evidence of active muscle diseases demonstrated by CPK ≥5 times UNL at Visit 1.
  20. History of any other concurrent serious illness or (except successfully treated basal and squamous cell carcinoma of the skin), within the past 5 years (e.g. tuberculosis, ).
  21. Positive HIV, hepatitis A (positivity of IgM), , or at Visit 1.
  22. History of excessive consumption of alcoholic beverages (consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking). For the remainder of the study, patients should agree to refrain from excessive alcohol consumption (i.e., >2 alcoholic beverages per day), to maintain their current dietary regimen, and to not alter their normal activity routines. (Note: patients should not drink alcohol for at least 24 hrs prior to any site visit).
  23. History of known allergy, sensitivity or intolerance to the study drugs and their formulation ingredients.
  24. Renal dysfunction demonstrated by abnormal \<50 mL/min/1.73 m2.
  25. History of * systemic therapy (intramuscular, intravenous, intra-articular, or oral route) within 3 months of the Visit 1 or anticipated requirement for systemic steroid therapy at Visit 1(however, topical, ophthalmic and inhaled steroids are allowed).

    * Clinically significant' (i.e., no more than 5 days of systemic steroids treatment within 3 months of Visit 1)

  26. NSAID use in excess of a reasonably prescribed dose and/or use in individuals with a history of complications resulting from these agents.
  27. Participation in any other clinical trial in the past 3 months in which product was taken and/or a medical device was utilized. Patients that were screened but not randomized for another study must wait 30 days to participate in Visit 1.
  28. Pregnancy (including a positive urine and serum pregnancy test at Visit 1), lactation or planned pregnancy/lactation during any time during the lead-in, study or follow-up periods.
  29. Patients on hormonal or hormone replacement therapy containing estrogen (progesterone based contraception and testosterone replacement therapy are permitted granted that dosing is stable for at least 3 months prior to Visit 1).
  30. Women of (WOCBP) and men, UNLESS using effective contraceptive methods, such as an intra-uterine device or other mechanical contraception method with condom or diaphragm and spermicide) throughout the study. For male patients, contraception measures (condom and spermicide) must be taken during the study, either by the male participant or his female partner. (Note: Enrolled females otherwise must be surgically sterilize for at least the 6 months preceding Visit 1 or , defined as 12 months with no menses without an alternative medical cause).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Saroglitazar magnesium 1 mg

    Saroglitazar magnesium 1 mg tablet orally once a day for 12 weeks

    Drug: Saroglitazar Magnesium 1 mg

  • Experimental
    Saroglitazar magnesium 2 mg

    Saroglitazar magnesium 2 mg tablet orally once a day for 12 weeks

    Drug: Saroglitazar Magnesium 2 mg

  • Experimental
    Saroglitazar magnesium 4 mg

    Saroglitazar magnesium 4 mg tablet orally once a day for 12 weeks

    Drug: Saroglitazar Magnesium 4 mg

  • Placebo comparator
    Placebo

    Placebo tablet orally once a day for 12 weeks

    Drug: Placebo

Interventions

  • Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks

  • Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks

  • Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks

  • DrugPlacebo

    Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage change in triglyceride cholesterol levels

    Percentage change in triglyceride cholesterol levels from baseline to Week 12.

    Time frame: 12 Weeks

Secondary outcomes

  1. Percentage change in TG-C

    Percentage change from baseline to Week 4 and 8 in TG-C

    Time frame: 8 Weeks

  2. Percentage change in lipid profile.

    Percentage change from baseline to 12 in lipid profile.

    Time frame: 12 Weeks

07

Study locations

33 sites
  • Medical Affiliated Research Center, Inc.
    Huntsville, Alabama 35801, United States
  • Encompass Clinical Research
    Encinitas, California 92023, United States
  • Integrated Research Center
    San Diego, California 92117, United States
  • Ventura Clinical Trials
    Ventura, California 93003, United States
  • Colorado Springs Health Partners
    Colorado Springs, Colorado 80906, United States
  • Meridien Research - Bradenton
    Bradenton, Florida 34201, United States
  • Meridien Research - Lakeland
    Lakeland, Florida 33805, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Meridien Research - Tampa
    Tampa, Florida 33634, United States
  • River Birch Research Alliance LLC
    Blue Ridge, Georgia 30513, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • Herman Clinical Research, LLC
    Suwanee, Georgia 30024, United States
  • Cedar-Crosse Research Center
    Chicago, Illinois 60607, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Centennial Medical Group
    Elkridge, Maryland 21075, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Einstein Clinical Research
    Charlotte, North Carolina 28277, United States
  • Triad Clinical Trials LLC
    Greensboro, North Carolina 27410, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Metabolic and Atherosclerosis Research Center
    Cincinnati, Ohio 45227, United States
  • Sterling Research Group, Ltd.
    Cincinnati, Ohio 45246, United States
  • Wells Institute for Health Awareness
    Kettering, Ohio 45429, United States
  • Ohio Clinical Research - Lyndhurst
    Lyndhurst, Ohio 44124, United States
  • Awasty Research Network, LLC
    Marion, Ohio 43302, United States
  • Ohio Clinical Research, LLC - Willoughby Hills
    Willoughby Hills, Ohio 44094, United States
  • Columbia Research Group, Inc.
    Portland, Oregon 97239, United States
  • PMG Research of Bristol, LLC
    Bristol, Tennessee 37620, United States
  • Jackson Clinic
    Jackson, Tennessee 38301, United States
  • Pioneer Research Solutions Inc.
    Houston, Texas 77099, United States
  • National Clinical Research - Richmond, Inc
    Richmond, Virginia 23294, United States
08

References and documents

Individual participant data

Plan to share: No — See above.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2017 (actual). Primary completion is estimated for Dec 2023, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2017
First posted
Mar 31, 2017
StartActual
Apr 6, 2017
Primary completionEst.
Dec 2023
CompletionEst.
Jan 2024
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03097107
Responsible party
Sponsor
First posted
Mar 31, 2017
Start date
Apr 6, 2017
Primary completion
Dec 2023 (estimated)
Completion
Jan 2024 (estimated)
Last update
Feb 8, 2023

Study contacts

Deven V Parmar, MD
study director · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion